LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.08 0.33

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.04

Max

3.19

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+29.87% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

7.8M

1.1B

Vorige openingsprijs

2.75

Vorige sluitingsprijs

3.08

Nieuwssentiment

By Acuity

50%

50%

167 / 350 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mrt 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Infosys Agrees to Acquire Stratus

25 mrt 2026, 23:58 UTC

Winsten

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mrt 2026, 23:58 UTC

Winsten

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mrt 2026, 23:41 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mrt 2026, 23:41 UTC

Winsten

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mrt 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Declines on Possible Technical Correction -- Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mrt 2026, 21:58 UTC

Marktinformatie

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mrt 2026, 21:37 UTC

Marktinformatie

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mrt 2026, 21:14 UTC

Acquisities, Fusies, Overnames

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mrt 2026, 21:13 UTC

Acquisities, Fusies, Overnames

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mrt 2026, 21:12 UTC

Acquisities, Fusies, Overnames

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

25 mrt 2026, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

25 mrt 2026, 20:33 UTC

Acquisities, Fusies, Overnames

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mrt 2026, 20:31 UTC

Winsten

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

29.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  29.87%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

167 / 350 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat